Long term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (omnicontrol study) : First-year follow-up report

Archivos Espanoles de Urologia

Volumn 57, Issue 4, 2004, Pages 451-460

  Palacio, A ^a   Hernandez C ^b   Marques A ^c   Prats, J ^d   Espinosa, F J ^e  

^a HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^b H Gregorio Marañorn   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d HParc Tauli   (Spain)

^e HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

BFH; Efficacy; LUTS; Tamsulosin; Tolerability

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; SULFONAMIDE; TAMSULOSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; TIME;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; SULFONAMIDES; TIME FACTORS;

EID: 4644351244     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ABRAMS P.: "New words for old: lower urinary tract symptoms for prostatism". BMJ, 308: 929, 1994.
2. GIRMAN C.J. et al: "Health-related quality of life associated with lower urinary tract symptoms in four countries". Urology, 51: 428, 1998.
3. BERRY S.J. et al. "The development of human benign prostatic hyperplasia with age". J. Urol., 132: 474, 1984.
4. GARRAWAY, W.M.; COLLINS, G.N.; LEE, R.J.: "High prevalence of benign prostatic hyperplasia in the community". Lancet, 338: 469, 1991.
5. ANGULO, et al.: "Evolución de la zona transicional de la próstata con la edad y desarrollo de HPB en una población española". Actas Urol. Esp., 21 (S): 172, 1997.
6. CAINE, M.: "Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia". Urol. Clin. North Am., 17: 641, 1990.
7. CHUTE, C.G. et al.: "The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol, 150: 85, 1993.
8. CHICHARRO MOLERO, J. et al: "Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older". J. Urol., 159: 878, 1998.
9. www.INE.es/inebase. "Avance de resultados de los Censos de Población y Vivienda" 2001.
10. CHAPPLE, C.R.: "Pharmacotherapy for benign prostatic hyperplasia: The potential for 1-adrenoceptor subtype-specific blockade". Br. J. Urol., 81(S1): 34, 1998.
11. SCHULMAN, C.C. et al: "Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: Analysis of a European, multinational, multicenter, open-label study". Eur. Urol., 36: 609, 1999.
12. SCHULMAN, C.C: "Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment". Urology, 62(S1): 24, 2003.
13. NARAYAN, P.; EVANS,. CP.; MOON, T: "Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol, 170: 498, 2003.
14. CHAPPLE, C.R. et al. "Tamsulosin, the first prostate-selective 1 A-adrenoceptor antagonist. A meta-analysis of two randomised, placebo-controlled multicenter studies in patients with benign prostatic obstruction" (symptomatic BPH). Eur. Urol., 29: 155, 1996.
15. LEPOR, H.: "Phase III multicenter, placebo-controlled study of tamsulosin in benign prostatic hyperplasia". Urology, 51: 892, 1998.
16. LEPOR, H.: "Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial". Urology, 51: 901, 1998.
17. MICHEL, M.C. et al. "Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: Does co-morbidity alter tolerability?". J. Urol., 160: 784, 1998.
18. SCHULMAN, C.C et al.: "Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia". J. Urol., 166: 1358, 2001.
19. MICHEL, M.C; DE LA ROSETTE J.J.: "Efficacy and safety of tamsulosin in the treatment of urologic diseases". Expert Opin Pharmacother, 5: 151, 2004.
20. MANN, R.D. et al.: 'The pharmacovigilance of tamsulosin: even data on 12484 patients". BJU International, 85: 446, 2000.
21. BARRY, M.J. et al.: "The American Urological Association symptom index for benign prostatic hyperplasia: The measurement committee of the American Urological Association". J. Urol., 148: 1549, 1992.
22. VELA NAVARRETE, R. et al.: "Cultural and linguistic validation, in Spanish, of the International Prostatic Symptoms Scale (I-PSS)". Actas Urol. Esp., 18: 841, 1994.
23. COCKETT, A.T.K. et al.: "Proceedings of the Third International Consultation on Benign Prostatic Hyperplasia (BPH)". Paris, SCI, p 651. 1996.
24. WILT, T.J.; McDONALD, R.; NELSON, D.: 'Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects". J. Urol., 167: 177, 2002.
25. NARAYAN, P.; TEWARI, A. and members of the United States 93-01 Study Group.: "A second phase III multicenter placebo controlled study of two dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia". J. Urol., 160: 1701, 1998.
26. PALACIO, A. et al.: "Tamsulosin: effect on sexual function in almost 3000 patients with LUTS managed in real life practice in Spain". BJU International, 86(S3): 20, 2000.
27. BATISTA, J.E. et al: "Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real life practice in Spain". Arch. Esp. Urol., 55: 97, 2002.
28. MICHEL, M.C. et al.: "Tamsulosin: Real life clinical experience in 19,365 patients". Eur. Urol., 34(S2): 37, 1998.
29. DE LA ROSETTE, JJMC. et al.: "Long-term risk of re-treatment of patients using -blockers for lower urinary tract symptoms". J. Urol., 167: 1734, 2002.
30. CARBALLIDO, J. et al.: 'Tamsulosin induces negative signalling for growth and survival in epithelial prostate cells in vivo in benign prostatic hyperplasia". Eur. Urol. Supplements, 2: 158, 2003.